The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study

Sponsor
Guangzhou Institute of Respiratory Disease
Study ID
NCT06851403
Status
Enrolling By Invitation

Conditions

  • Asthma in Children

Eligibility Criteria

Sex
ALL
Age
4 Years - 16 Years
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — DRUG
    initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks

Study Details

Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.

Key Dates

Start date
Jan 30, 2022
Status verified
Feb 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025

Study Design

Enrollment
213 participants (estimated)

Arms

  • Arm: Case group

Primary Outcome Measure

FEV1 [ Time Frame: From enrollment to the end of treatment through study completion, an average of 1 year ]

Related Studies